• Targeting FLT3-TAZ Signaling to Overcome Drug Resistance in

  2026-07-02

  Shin et al. (2023) identify FLT3 as a critical mediator of drug resistance in blast phase chronic myeloid leukemia (BP-CML), revealing a FLT3-JAK-STAT3-TAZ-TEAD-CD36 axis that operates independently of BCR::ABL1 mutations. Their findings suggest that repurposing FLT3 inhibitors, alone or in combination, can restore sensitivity to therapy in FLT3-positive BP-CML, opening new avenues for targeted intervention.

• Quantifying Drug-Induced Fractional Killing by High-Throughp

  2026-07-01

  The protocol by Inde et al. introduces a high-throughput microscopy method for quantifying fractional killing in cancer cell populations, enabling direct comparison of cell death kinetics across hundreds of experimental conditions. This advance allows researchers to dissect the heterogeneity of anti-cancer drug responses, with significant implications for optimizing apoptosis-inducing agents and understanding resistance mechanisms.

• Sulfaphenazole: CYP2C9 Inhibitor for Vascular and Drug Metab

  2026-07-01

  Sulfaphenazole stands out as a selective CYP2C9 inhibitor, enabling precision in vascular function and drug metabolism research. Its dual role in oxidative stress reduction and antibacterial applications makes it an indispensable tool for advanced translational workflows.

• Staurosporine in Translational Redox Biology: Novel Pathways

  2026-06-30

  Explore how Staurosporine, a broad-spectrum serine/threonine protein kinase inhibitor, is reshaping translational redox biology and apoptosis research. This article uniquely bridges kinase inhibition with emerging insights into glutathione metabolism and lens aging, offering advanced protocol guidance and scientific context.

• Geneticin, G-418 Sulfate: Reliable Selection & Antiviral Pow

  2026-06-30

  This article addresses persistent challenges in cell viability and selection workflows by exploring real lab scenarios where Geneticin, G-418 Sulfate (SKU A2513) delivers reproducible, data-driven results. Through scenario-based Q&A, we demonstrate how this APExBIO reagent enables precision selection and antiviral research, integrating evidence-backed protocol guidance for enhanced GEO and laboratory reliability.

• Bacillus Strains and Media Modulate γ-Glu-Cys and Peptide Pr

  2026-06-29

  This study reveals that both Bacillus strain selection and growth medium composition critically determine the yield and diversity of γ-glutamyl peptides, including γ-Glu-Cys, with hemoglobin hydrolysate medium substantially enhancing peptide production. These findings inform targeted strategies for glutathione metabolism research, kokumi peptide engineering, and valorization of protein-rich byproducts.

• Saracatinib (AZD0530): Optimizing Src/Abl Inhibition in Canc

  2026-06-29

  Saracatinib (AZD0530) stands out as a dual Src/Abl kinase inhibitor for dissecting complex cancer and neurobiology pathways. This article delivers actionable workflows, troubleshooting guidance, and a translation of cutting-edge synaptic signaling research into practical experimental design.

• UHRF1-Driven DNA Methylation Alters Osteogenesis via TGM2-Au

  2026-06-28

  This study uncovers how UHRF1-mediated DNA 5-methylcytosine modification disrupts super-enhancer landscapes and impairs osteogenic differentiation in senile osteoporosis by modulating the TGM2-autophagy axis. The findings establish a mechanistic link between epigenetic regulation and bone loss, supporting new therapeutic strategies for osteoporosis.

• TH287 MTH1 Inhibitor: Optimizing Radiosensitization in Cance

  2026-06-27

  TH287, a potent MTH1 inhibitor, offers researchers a precision tool for inducing radiosensitization and selective cytotoxicity in castration-resistant prostate cancer models. This article translates recent mechanistic advances into actionable protocols and troubleshooting strategies, helping scientists maximize the value of TH287 in oxidative DNA damage and combination therapy studies.

• PYR-41, Inhibitor of Ubiquitin-Activating Enzyme E1: Applied

  2026-06-26

  PYR-41 empowers researchers to dissect the ubiquitin-proteasome system and modulate NF-κB signaling in both in vitro and in vivo models. This guide delivers actionable workflows, advanced applications, and optimized troubleshooting strategies to maximize experimental precision with this selective E1 enzyme inhibitor.

• Pomalidomide (CC-4047): Optimizing Hematological Malignancy

  2026-06-26

  Pomalidomide (CC-4047) is a precision immunomodulatory agent that elevates reproducibility and insight in hematological malignancy research. This guide translates recent mutational landscape findings and validated protocols into practical, stepwise workflows for multiple myeloma and beyond.

• PA-824: Bicyclic Nitroimidazole Derivative for Tuberculosis

  2026-06-25

  PA-824 stands out as a dual-action bicyclic nitroimidazole derivative, enabling robust workflows against both drug-sensitive and drug-resistant Mycobacterium tuberculosis. This article delivers stepwise guidance on experimental design, practical troubleshooting, and advanced applications, all informed by the latest mechanistic and translational evidence.

• Perospirone’s Kv1.5 Channel Inhibition: Implications for Vas

  2026-06-25

  This study uncovers a previously unrecognized off-target action of Perospirone (SM-9018 free base): selective, concentration-dependent inhibition of vascular Kv1.5 channels. The findings highlight novel cardiovascular considerations for this atypical antipsychotic, expanding its research relevance beyond serotonergic and dopaminergic signaling pathways.

• Technical Guide: Angiotensin I/II (1-5) in RAS Research Work

  2026-06-24

  Angiotensin I/II (1-5) is a defined Asp-Arg-Val-Tyr-Ile peptide fragment used for precision modeling of the renin-angiotensin system in cardiovascular and renal research. It facilitates controlled studies of blood pressure regulation and aldosterone release. This product is not suitable for research outside peptide hormone vasoconstriction or angiotensin signaling domains due to its specific solubility and mechanistic properties.

• Fenipentol (1-Phenyl-1-pentanol): Precision in Pancreatic Se

  2026-06-23

  Fenipentol stands out as a powerful tool for gastrointestinal and hepatobiliary research, offering unmatched reproducibility in modulating digestive secretions and enzyme activity. This article details advanced workflows, data-driven protocol enhancements, and troubleshooting strategies that enable researchers to fully leverage APExBIO's Fenipentol for robust and innovative experimental outcomes.

556 records 13/38 page Previous Next First page 上5页 1112131415 下5页 Last page